|
CELL GENESYS INC, (CEGE) Stock Research Free Stock Rating
|
|
| |
| Company Profile |
| |
|
Cell Genesys, Inc., a biotechnology company, engages in the research, development, and commercialization of biological therapies for patients with cancer. The company develops cell-based cancer vaccines, oncolytic virus therapies, and antiangiogenesis therapies to treat various types of cancer. Its clinical stage cancer programs comprise cell- or viral-based products that have been genetically modified during product development to impart disease-fighting characteristics. The companys clinical-stage programs include GVAX cancer vaccines and oncolytic virus therapies. Cell Genesys GVAX cancer vaccines program includes Phase 3 clinical trials for prostate cancer and Phase 2 clinical trials for pancreatic cancer and leukemia. The companys oncolytic virus therapies program includes a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer and other types of cancer. It has a strategic alliance with Novartis AG to develop and commercialize oncolytic virus therapies, and has collaboration agreements with Medarex, Inc. and Abgenix, Inc. Cell Genesys was incorporated in 1988 and is headquartered in South San Francisco, California.
|
CELL GENESYS INC Related |
|
Cell Genesys Focused on the development and commercialization of novel biological therapies for patients with cancer.
|
|
CEGE: Profile for Cell Genesys, Inc. - Yahoo! Finance See the company profile for Cell Genesys, Inc. (CEGE) including business summary, industry/sector information, number of employees, business summary, corporate ...
|
|
Cell Genesys, Inc. Cell Genesys Announces "Modified Dutch Auction" Tender Offer for up to $80 ... Cell Genesys to Present at the Rodman & Renshaw 10th Annual Healthcare Conference ...
|
|
